PRANA BIOTECHNOLOGY
PRANA BIOTECHNOLOGY operates in Diversified Metals & Mining.
PRANA BIOTECHNOLOGY (PBN) - Total Liabilities
Latest total liabilities as of June 2024: €5.43 Million EUR
Based on the latest financial reports, PRANA BIOTECHNOLOGY (PBN) has total liabilities worth €5.43 Million EUR as of June 2024.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
PRANA BIOTECHNOLOGY - Total Liabilities Trend (2016–2024)
This chart illustrates how PRANA BIOTECHNOLOGY's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
PRANA BIOTECHNOLOGY Competitors by Total Liabilities
The table below lists competitors of PRANA BIOTECHNOLOGY ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Biome Technologies Plc
LSE:BIOM
|
UK | GBX3.23 Million |
|
iSun, Inc.
NASDAQ:ISUNQ
|
USA | $53.58 Million |
|
RIALTO ENERGY
BE:R1Y
|
Germany | €39.45 Million |
|
NB Distressed Debt New Glb
LSE:NBDG
|
UK | GBX2.75 Million |
|
SENTUL CITY -A- (5S4.SG)
STU:5S4
|
Germany | €5.94 Trillion |
Liability Composition Analysis (2016–2024)
This chart breaks down PRANA BIOTECHNOLOGY's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.54 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.39 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.28 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how PRANA BIOTECHNOLOGY's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for PRANA BIOTECHNOLOGY (2016–2024)
The table below shows the annual total liabilities of PRANA BIOTECHNOLOGY from 2016 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-06-30 | €5.43 Million | +20.44% |
| 2023-06-30 | €4.50 Million | -23.57% |
| 2022-06-30 | €5.89 Million | +89.20% |
| 2021-06-30 | €3.12 Million | +13.00% |
| 2020-06-30 | €2.76 Million | -17.83% |
| 2019-06-30 | €3.36 Million | +26.86% |
| 2018-06-30 | €2.64 Million | +66.25% |
| 2017-06-30 | €1.59 Million | -32.53% |
| 2016-06-30 | €2.36 Million | -- |